Biopharmaceuticals
Cerevance is developing therapeutics that act on target proteins expressed highly selectively in brain cell types that die in disease, play a key role in the disease process, or are located in brain circuits disrupted by disease. In some cases, our NETSseq platform has revealed that a target protein is dysregulated in human disease tissue samples. We believe that advancing drugs that act on selectively expressed targets will enable us to deliver more effective medicines that slow disease progression or provide symptomatic relief while causing fewer “on-target” side effects.
Craig Thompson
Brad Margus
Nice Insight/That’s Nice
89 Fifth AvenueFifth FloorNew YorkNY 10003-3020
New York – San Diego – ChicagoLondon – Frankfurt – Shanghai
Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.